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Abstract  23 
There is a growing interest to study human dermal exposure to a large number of chemicals, 24 
whether in the indoor or outdoor environment. Such studies are essential to predict the 25 
systemic exposure to xenobiotic chemicals for risk assessment purposes and to comply with 26 
various regulatory guidelines. However,  very little is currently known about human dermal 27 
exposure to persistent organic pollutants. While recent pharmacokinetic studies have 28 
highlighted the importance of dermal contact as a pathway of human exposure to brominated 29 
flame retardants, risk assessment studies had to apply assumed values for percutaneous 30 
penetration of various flame retardants (FRs) due to complete absence of specific 31 
experimental data on their human dermal bioavailability. Therefore, this article discusses the 32 
current state-of-knowledge on the significance of dermal contact as a pathway of human 33 
exposure to FRs. The available literature on in vivo and in vitro methods for assessment of 34 
dermal absorption of FRs in human and laboratory animals is critically reviewed.  Finally, a 35 
novel approach for studying human dermal absorption of FRs using in vitro three-36 
dimensional (3D) human skin equivalent models is presented and the challenges facing future 37 
dermal absorption studies on FRs are highlighted. 38 
 39 
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List of Acronyms 47 
BFRs brominated flame retardants 
BPA bisphenol A 
BTBPE 1,2-bis(2,4,6 tribromophenoxy)ethane 
DBDPE Decabromodiphenylethane 
EU European Union 
EVCAM european centre for validation of alternative methods 
FRs flame retardants 
FT full-thickness skin 
HBCD hexabromocyclododecane 
HSE human skin equivalent 
KC keratinocytes 
KOW octanol/water partition coefficient 
LC langerhans cells 
NBFRs novel brominated flame retardants 
OATP organic anion transporting polypeptides 
OECD organisation for economic co-operation and development 
PA percutaneous absorption 
PBDEs polybrominated diphenyl ethers 
PBT persistent, bioaccumulative and toxic 
PCBs polychlorinated biphenyls 
PFRs organophosphate flame retardants 
PK pharmacokinetic 
POPs persistent organic pollutants 
RDP resorcinol bis-diphenylphosphate 
SC stratum corneum 
RHE reconstructed human epidermis 
TBB 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 
TBBPA tetrabromobisphenol A 
TBPH Bis(2-ethylhexyl)tetrabromophthalate 
TCEP tris(2-chloroethyl) phosphate 
TCIPP tris(2-chloro-1-methylethyl) phosphate 
TDCPP tris(1,3-dichloro-2-propyl) phosphate 
TRIS tris (dibromopropyl) phosphate 
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USEPA United States environment protection agency 
48 
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Introduction 49 
 Organic flame retardants (FRs) are a diverse group of chemicals used to prevent or reduce 50 
the flammability and combustibility of polymers and textiles. The major members of this 51 
group are polybrominated diphenyl ethers (PBDEs), hexabromocyclododecane (HBCD), 52 
tetrabromobisphenol A (TBBP-A), novel brominated flame retardants (NBFRs), as well as 53 
organophosphate flame retardants (PFRs) (Ghosh, et al. 2011; van der Veen and de Boer 54 
2012). 55 
Although polychlorinated biphenyls (PCBs) were mainly applied as heat transfer fluids in 56 
electric equipment, capacitors and transformers, one of their major advantages as heat 57 
transfer fluids was flame-retardancy. Thus, PCBs were highly desirable for applications 58 
where fire was a threat to life and property, such as in electrical equipment in commercial 59 
buildings, hospitals, in hydraulic systems in foundries, and in heat transfer systems. 60 
Furthermore, PCBs were also applied to flame-proof polyimide (nylon-type) and polyolefin 61 
yarns. Due to their persistent, bioaccumulative and toxic (PBT) properties, the production and 62 
usage of PCBs were banned throughout most of the industrialized world in the 1970s 63 
(Erickson and Kaley 2011; Fiedler 2001).  64 
PBDEs have found wide application as FRs for plastics, textiles, electronics casings and 65 
circuitry. The fully brominated product (DecaBDE) dominated worldwide production with a 66 
global demand of 56,100 t in 2001, compared to 7,500 and 3,790 t for the less brominated 67 
PentaBDE  and OctaBDE formulations, respectively (BSEF 2013). In 2001, the world market 68 
demand for HBCD was 16,700 tons, 57% of which was in Europe (Covaci, et al. 2006). The 69 
principal application of HBCD is in expanded and extruded polystyrene foams used for 70 
building insulation , but it has also been used to flame retard textiles and housing for 71 
electrical items (KEMI (National Chemicals Inspectorate) 2008). TBBP-A is the most widely 72 
used BFR with a production volume of 170,000 tons in 2004, applied mainly for epoxy resins 73 
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used in printed circuit boards of electric and electronic equipments (Covaci, et al. 2009a). As 74 
PBDEs, HBCD, and ~20% of the production of TBBP-A are blended physically within (and 75 
referred to as “additive” FRs) rather than bound chemically (and known as “reactive” FRs) to 76 
polymeric materials; they migrate from products, following which their persistence and 77 
bioaccumulative character leads to contamination of the environment including humans 78 
(Harrad, et al. 2010a). This is of concern owing to their potential environmental and 79 
toxicological risks including: endocrine disruption, neurodevelopmental and behavioural 80 
disorders, hepatotoxicity and possibly cancer (Darnerud 2008; Hakk 2010; Wikoff and 81 
Birnbaum 2011). Moreover, the few data available from human epidemiological studies 82 
imply effects on: male reproductive hormones (Johnson, et al. 2013; Meeker, et al. 2009), 83 
semen quality (Akutsu, et al. 2008), thyroid hormone homeostasis (Turyk, et al. 2008), 84 
cryptorchidism (Main, et al. 2007), hormone levels and fecundability in adult women 85 
(Harley, et al. 2010), as well as lower birth weight and length (Chao, et al. 2007; Lignell, et 86 
al. 2013). Such evidence has contributed to complete EU bans for the Penta- and Octa-BDE 87 
formulations, and restrictions on the use of Deca-BDE (Roberts, et al. 2012). In addition, 88 
PBDEs associated with Penta- and Octa-BDE are listed under the UNEP Stockholm 89 
Convention on POPs, while Deca-BDE is currently under consideration for listing under 90 
Annexes A, B and/or C of the convention (Stockholm convention on POPs 2009). 91 
Furthermore, HBCD will be phased out following its recent listing under Annex A of the 92 
Stockholm Convention (Stockholm convention on POPs 2013). Despite such restrictions on 93 
their production and use, human exposure to PBDEs and HBCD is likely to continue for 94 
some time, given the ubiquity of flame retarded products remaining in use and entering the 95 
waste stream, coupled with the environmental persistence of these BFRs (Harrad and 96 
Diamond 2006).  97 
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These restrictions on the use of PBDEs and HBCD have paved the way for the use of NBFRs 98 
as replacements with an estimated global production volume of 100,000 tonnes in 2009 99 
(Harrad and Abdallah 2011). Major NBFRs are: DBDPE (Decabromodiphenylethane), 100 
BTBPE (1,2-bis(2,4,6 tribromophenoxy)ethane), TBB (2-ethylhexyl 2,3,4,5-101 
tetrabromobenzoate), and TBPH (Bis(2-ethylhexyl)tetrabromophthalate) (further details are 102 
provided in Table SI-1). While information regarding the environmental occurrence of 103 
several NBFRs has become available recently (Covaci, et al. 2011), very little is known about 104 
their toxicological properties and the pathways and magnitude of human exposure to these 105 
chemicals. Nevertheless, several NBFRs bear striking structural similarity to PBDEs (e.g. 106 
DBDPE is a very close analogue of BDE-209) and are reported to have similarly low vapour 107 
pressures and water solubilities, as well as high KOW values, and PBT characteristics (Covaci, 108 
et al. 2011; Harrad and Abdallah 2011). 109 
In addition to BFRs, PFRs have been associated with a wide range of applications (Table SI-110 
1). Likely linked to the aforementioned restrictions on PBDEs, EU market demand for PFRs 111 
increased from 83,700 tons in 2004 to 91,000 tons in 2006 (EFRA 2007). Tris(2-chloroethyl) 112 
phosphate (TCEP), tris(2-chloro-1-methylethyl) phosphate (TCIPP) and tris(1,3-dichloro-2-113 
propyl) phosphate (TDCPP) were all subject to an EU risk assessment process under an 114 
Existing Substances Regulation (EEC 793/93) (Regnery and Puttmann 2010). Despite less 115 
stability and overall environmental persistence than PBDEs, they were classified as persistent 116 
organic compounds in the aquatic environment and reported to fulfil PBT criteria. In 117 
addition, several studies have reported them to display adverse effects including reproductive 118 
toxicity and carcinogenic effects on lab animals (Regnery, et al. 2011). Hence TCEP is 119 
classified by the EU as a “potential human carcinogen” (Regnery and Puttmann 2010),  while 120 
TDCPP is classified under regulation EC 1272/2008 as a category 2 carcinogen (ECHA 121 
2010). 122 
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 123 
Human exposure to FRs. Several studies have reported on levels of different FRs in various 124 
environmental and human matrices (Covaci, et al. 2011; Covaci, et al. 2009b; Harrad, et al. 125 
2010b; Law, et al. 2014; van der Veen and de Boer 2012). Current understanding is that non-126 
occupational human exposure to BFRs occurs mainly via a combination of diet, ingestion of 127 
indoor dust, dermal contact with dust/consumer products, and inhalation of indoor air (Figure 128 
1) (Abdallah, et al. 2008a; Frederiksen, et al. 2009; Watkins, et al. 2011). The exact 129 
contribution of these pathways varies substantially between chemicals, between individuals 130 
according to lifestyle, and is further complicated by international variations in FR use 131 
(Abdallah and Harrad 2009; Abdallah, et al. 2008a; Abdallah, et al. 2008b; Harrad, et al. 132 
2008b). While it is established that the main exposure route to several POPs (e.g. PCBs and 133 
DDT) is through diet, studies from North America report indoor dust (via ingestion or dermal 134 
contact) as the major exposure pathway for all age groups to PBDEs contributing 70-80% to 135 
the average overall daily exposure (Lorber 2008; Trudel, et al. 2011). Elsewhere, while dust 136 
ingestion appears particularly important for toddlers and young children; other exposure 137 
pathways make substantial contributions to the overall adult intake of BFRs (Abdallah, et al. 138 
2008a; Harrad, et al. 2010b; Harrad, et al. 2008a; Roosens, et al. 2009). In contrast to PBDEs, 139 
only a  few studies are available that address human exposure to NBFRs and PFRs (Ali, et al. 140 
2012; Covaci, et al. 2011; Stapleton, et al. 2011). Currently very little is known about dermal 141 
exposure as a route of human exposure to FRs in indoor dust or FR-treated products. This 142 
paucity of information was evident in the EU risk assessment reports on TBBPA (EU Risk 143 
Assessment Report 2006) and BDE-209 (EU Risk Assessment Report 2002) where the lack 144 
of experimental data has led to the assumption of dermal absorption efficiencies based on 145 
consideration of compound-specific physicochemical properties and extrapolation from data 146 
available for PCBs. Furthermore, several authors have discussed the absence of experimental 147 
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data on dermal absorption of various FRs and highlighted the potential inaccuracies of 148 
current estimates of human exposure to these FRs owing to a general lack of knowledge on 149 
the percutaneous route (Boyce, et al. 2009; Garner, et al. 2006; Trudel, et al. 2011; U.S. EPA 150 
1992). Therefore, the lack of experimental information on human dermal uptake of FRs from 151 
dust and source materials, represents an important research gap that hampers accurate 152 
assessment of human exposure to FRs. However, efforts to fill this gap are hindered by 153 
several difficulties including: ethical issues encountered with human studies, inter-species 154 
variation in dermal structure and uptake that cast doubt on the accuracy of extrapolation or 155 
allometric scaling of animal data to humans, and tighter regulations on in vivo tests involving 156 
animals. 157 
Against this backdrop, this paper: (a) provides a critical review of the current state-of-158 
knowledge on dermal absorption of FRs, (b) discusses the paradigm shift in toxicity testing 159 
from in vivo to in vitro dermal bioavailability studies and (c) suggests effective novel 160 
approaches to studying human dermal uptake of FRs, with special emphasis on in vitro 3D 161 
human skin percutaneous assays, that are finding increasing application in the pharmaceutical 162 
and cosmetics sectors (Gibbs, et al. 2013; Kandarova, et al. 2013; Tornier, et al. 2010). 163 
 164 
Skin as a barrier for systemic exposure to xenobiotic chemicals.  165 
Skin is  the largest body organ, with a surface area of ~ 2 m2 and weighing about 5 kg in adult 166 
humans (Godin and Touitou 2007). This multi-layered organ acts mainly to protect the body 167 
from the surrounding environment, thus froming an efficient permeation barrier for 168 
exogenous molecules. Human skin is formed of 3 main layers, namely: epidermis, dermis and 169 
hypodermis (Figure 2). The epidermis (outermost) is a non-vascular layer, which has a 170 
protective role as a barrier to penetration of chemicals to the underlying vascular dermis. The 171 
healthy human epidermis comprises 4 layers (stratum corneum, stratum granulosum, stratum 172 
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spinosum and stratum basale) separated from the dermis by the basement membrane 173 
(Breitkreutz, et al. 2013). The barrier properties of the skin lie mainly within the stratum 174 
corneum (SC), which has about 16 layers and takes about two weeks to completely 175 
desquamate (Hoath and Leahy 2003). This highly hydrophobic layer is composed of 176 
differentiated non-nucleated cells, corneocytes, which are filled with keratins and embedded 177 
in the lipid domain. Percutaneous penetration of molecules through the SC occurs mainly via 178 
passive diffusion but may also occur via sweat glands and hair follicles directly to the dermis. 179 
Although little is known about the expression and function of influx transport proteins in 180 
human skin and their role in dermal uptake of xenobiotics, The role of organic anion 181 
transporting polypeptides (OATP) in mediating the active transport process of large organic 182 
cations via human keratinocytes was highlighted (Schiffer, et al. 2003). Chemical residues 183 
limited to the epidermis will be eliminated from the exposed skin by desquamation and 184 
willnot be available for systemic distribution (Aggarwal, et al. 2014). 185 
 186 
Significance of dermal absorption as a pathway of human exposure to FRs.  187 
Although several studies have highlighted the importance of indoor dust ingestion as a 188 
pathway for human exposure to various FRs, few reports have discussed human dermal 189 
exposure to such contaminants (Stapleton, et al. 2012; Stapleton, et al. 2008; Watkins, et al. 190 
2011). Watkins et al. (Watkins, et al. 2011) reported a strong positive correlation between 191 
PBDE levels on hand wipes (assumed to result from hand contact with contaminated dust or 192 
flame-retarded products) and PBDE concentrations in serum from American adults. While 193 
concentrations of PBDEs in indoor dust were strongly correlated with those in hand wipes, 194 
and infrequent hand-washers had 3.3 times the levels of PBDEs in their handwipes than did 195 
frequent hand-washers; correlation could not be established directly between PBDE 196 
concentrations in indoor dust and their levels in serum (Watkins, et al. 2011). In a more 197 
11 
 
recent contribution, significant associations between concentrations of TCEP, TCIPP, 198 
TDCPP, HBCD, TBB and TBPH in children handwipes and house dust were observed 199 
(Stapleton, et al. 2014). Another recent study reported 2-3 times increase of median 200 
concentrations of penta-BDE, TBB, and TBPH in paired handwipe samples of 11 gymnasts 201 
after practice compared to before (Carignan, et al. 2013). This opens up the possibility that 202 
FRs in dust may also be an indicator of another exposure pathway, such as direct dermal 203 
uptake of FRs present in treated goods (e.g. games consoles, remote controls, and fabrics). A 204 
pivotal issue for risk assessment studies is the influence of indoor contamination with FRs on 205 
human body burdens. Understanding of this remains incomplete. One approach is that of 206 
Lorber (Lorber 2008) who used a simple pharmacokinetic (PK) model to predict the body 207 
burdens of PBDEs in American adults using intake data from different exposure pathways. 208 
Predicted body burden were compared with measured data and the relationship between 209 
external and internal exposure discussed. Since then, a few studies have applied similar PK 210 
models with slight adjustments to further understanding of the relationship between 211 
concentrations of PBDEs, HBCD and TBBP-A in the environment and human body burdens 212 
(Abdallah and Harrad 2011; Johnson-Restrepo and Kannan 2009; Trudel, et al. 2011). 213 
Further to identifying various research gaps including the bioavailability of FRs following 214 
ingestion of indoor dust and the elimination half-lives of these compounds in human,  One 215 
major outcome of such PK studies is the highlighted potential importance of dermal contact 216 
with indoor dust and/or FR-containing items as a pathway of exposure to BFRs. To illustrate, 217 
dermal uptake was reported as the 2nd most important contributor( following dust ingestion) 218 
to PBDE body burdens of Americans. This was despite a very conservative assumption – 219 
made in the absence of experimental data - that only 3% of PBDEs with which dermal 220 
contact occurred (via adherence of indoor dust to the skin) were absorbed (Lorber 2008). 221 
Moreover, a recent PK model reported ingestion of diet and dust, as well as dermal exposure 222 
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to dust to constitute the major factors influencing human body burdens of PBDEs in both 223 
Americans and Europeans. Once again, these conclusions were founded on low assumed 224 
values of dermal absorption efficiency (2.5-4.8%) (Trudel, et al. 2011). Neither study 225 
considered potential dermal absorption following contact with FR-treated items and assumed 226 
percutaneous penetration fractions based on values reported for dermal absorption of dioxins 227 
and PCBs from soil in laboratory animal models (Lorber 2008; Trudel, et al. 2011). Boyce et 228 
al. (2009) applied a Monte Carlo-based mathematical approach for assessment of human 229 
exposure to TBBPA, DBDPE and BDE-209 via indoor dust ingestion and dermal contact. 230 
Based on physicochemical properties, analogy with data for PCBs and the absence of any 231 
chemical-specific studies, dermal absorption values of 10%, 0.1% and 1% were used for 232 
TBBPA, DBDPE and BDE-209, respectively. Results revealed dermal contact with indoor 233 
dust made significant contributions (15 - 40%) to estimates of overall human exposure to 234 
these BFRs in North America and Europe. The authors highlighted that at such significant 235 
contribution levels; inaccuracies in the dermal absorption factors applied could have dramatic 236 
effects on exposure assessments (Boyce, et al. 2009).  237 
 238 
Transdermal metabolism of xenobiotics. 239 
Besides the role of the stratum corneum as the major structure for epidermal barrier function, 240 
there is increasing evidence that xenobiotic metabolizing enzymes and transport proteins 241 
function as a second biochemical barrier of the skin (Esser and Goetz 2013; Gundert-Remy, 242 
et al. 2014; Wiegand, et al. 2014). Currently, very little is known about the transdermal 243 
metabolism of flame retardant chemicals. Garner and Matthews confirmed extrahepatic 244 
dermal metabolism of mono- to hexa- PCBs in F-344 male rats. However, the exact chemical 245 
structure of the formed metabolites was not confirmed (Garner, et al. 2006). Another in vitro 246 
study reported the dermal metabolism of BDE-209 and TDCPP to be minimal in adult female 247 
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mice (Hughes, et al. 2001). However, an extensive literature exists on the capacity of human 248 
skin to metabolise various chemical compounds. Recent findings indicate that human skin 249 
possesses not only multiple cytochrome P450 isoenzymes, but also influx and efflux 250 
transporter proteins. While the pattern of cytochrome P450 isoenzymes in the skin differs 251 
from the pattern in the liver, It seems likely that the skin can participate in both Phase I (e.g. 252 
oxidation, reduction and hydrolysis) and Phase II (e.g. glucuronidation and acetylation) 253 
metabolic reactions (Gundert-Remy, et al. 2014; Merk 2009). Moreover, human skin 254 
cells contained at least five different esterases reported to act on simple ester bonds in 255 
organophosphate compounds (paraoxon and bis(4-nitrophenyl)phosphate). Therefore, dermal 256 
biotransformation may play an important role in the ultimate fate and bioavailabilty of FRs in 257 
the skin, especially for PFRs and NBFRs which have labile functional groups. 258 
 259 
In vivo dermal bioavailability studies 260 
While the most reliable method for assessment of dermal absorption for human risk 261 
assessment would involve study of human volunteers; technical and ethical constraints means 262 
their use has been and will likely remain limited (Jakasa and Kezic 2008). Although the use 263 
of in vivo animal models has been strongly discouraged (European Commission and 264 
absorption 2004; Howes, et al. 1996), their application for dermal risk assessment is of value 265 
because they represent an intact physiological and metabolic system when the use of human 266 
volunteers is not possible. Furthermore, in vivo animal models (especially rats) have long 267 
been used by different industrial and regulatory institutions to provide data on various 268 
toxicokinetic and toxicodynamic parameters, as well as dermal absorption (Zendzian 2000). 269 
While dermal uptake of environmental contaminants (e,g, polycyclic aromatic hydrocarbons, 270 
phthalates and pesticides) from soil and sediment has been reviewed (Spalt, et al. 2009), very 271 
little is known about the uptake of flame retardants via skin (Table 1). Schmid et al. studied 272 
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the dermal absorption of PCBs in one human volunteer (52 year old male, 65 kg body 273 
weight) (Schmid, et al. 1992). The volunteer was exposed to a mixture of  8 tetra- to hepta- 274 
13C-PCBs for different time spans using cotton cloth and aluminium foil as carrier materials 275 
to mimic real life situations of skin contact with PCB-contaminated clothes or metal surfaces. 276 
After exposure the skin was washed subsequently with water and ethanol. Non-absorbed 13C-277 
PCBs were determined in the washing solvents and in the carrier materials, while the 278 
bioavailable fraction was measured in plasma samples collected at 0.5-6 days post-exposure. 279 
Results revealed low percutaneous absorption (PA) of target PCBs equivalent to 6 % of the 280 
absorption after oral intake of the same amount. The absorption rate was largely dependent 281 
on the site of administration, on the carrier material (higher from the aluminium foil than the 282 
cotton cloth) and almost not on the amount administered where the percentage uptake 283 
remained constant at long (8 hours) and short (10 min) exposure times(Schmid, et al. 1992). 284 
Similar PA values (3.4-4.5 %) were reported in Rhesus monkeys exposed to PCB-285 
contaminated soil for 24 h (Mayes, et al. 2002). The difference between the calculated PA 286 
values for soil PCBs in this study and the 14% dermal absorption factor used by the USEPA 287 
(U.S. EPA 1992) was attributed mainly to soil organic content in addition to particle size, 288 
skin residence time and contaminant “aging” in the soil. The percutaneous absorption of 14C-289 
Aroclor 1260 in test monkeys was determined by measuring the radioactivity in excreta 290 
(equation 1) (Mayes, et al. 2002). 291 
 292 
An important point is that the model used in equation 1 and in all in vivo studies in humans or 293 
surrogate species where the animal is not sacrificed, cannot account for any test compounds 294 
sequestered within the skin (Mayes, et al. 2002; Spalt, et al. 2009). This may lead to 295 
substantial underestimation of the actual dermal uptake of persistent lipophilic compounds 296 
which would eventually (within days) be systemically absorbed from the skin depot of the 297 
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exposed organism. For such compounds, for which the outcome of concern is typically not 298 
acute toxicity, inclusion of skin burden is necessary (Spalt, et al. 2009). While adjustment for 299 
excretion following intravenous administration may be employed, this has associated 300 
uncertainty and presumes no difference in the excretory pattern associated with dermal and 301 
intravenous administration used as a reference. The importance of this concept of 302 
contaminant skin depot was confirmed by Garner and Mathews (Garner and Matthews 1998). 303 
These authors applied 0.4 mg/kg body weight of a mixture of radiolabeled mono- to hexa- 304 
PCBs in acetone to a 1 cm2 hairless skin area at the back of adult male F-344 rats. 305 
Distribution of radioactivity in the dose site and selected tissues was determined by serial 306 
sacrifice at time points up to 2 weeks. Results revealed the dermal penetration of test 307 
compounds to vary inversely with degree of chlorination and at 48 h ranged from ca. 100% 308 
for mono-PCB to ca. 30% for hexa-PCB. Although the maximum internal exposure to Mono-309 
PCB was at 4 h (37% of the dose present in tissues), only 0.2% of the absorbed dose 310 
remained in the tissues after 2 weeks. In contrast, tetra-PCB internal exposure was the 311 
greatest with ca. 85% of the total absorbed dose present in tissues 72 h postadministration. 312 
Furthermore, hexa-PCB equivalents in tissues continued to rise through 2 weeks postdose 313 
(~15% of absorbed dose) since systemic absorption from epidermis depots was still 314 
incomplete when the study was terminated. While rat skin favoured the rapid absorption of 315 
lower chlorinated PCBs; their relatively rapid metabolism and elimination, suggests lower 316 
body burdens of the less chlorinated congeners compared to higher molecular weight PCBs 317 
which penetrate less rapidly, but persist at the site of exposure and slowly enter the systemic 318 
circulation (Garner and Matthews 1998). In another contribution, Garner et al (Garner, et al. 319 
2006) used the same animal model to study the disposition of mono- to hexa- PCBs following 320 
dermal administration. Results confirmed higher chlorinated PCBs to be slowly absorbed and 321 
accumulated in the adipose and skin. Interestingly, excretion and metabolic profiles following 322 
16 
 
dermal dosing tended to differ from profiles following equivalent intravenous doses. This 323 
was attributed to first pass metabolism occurring at the dermal dose site. The study further 324 
suggested that the rate of absorption, and consequently disposition of PCBs following dermal 325 
exposure, may be mediated, either in part or fully, by transdermal metabolism (Garner, et al. 326 
2006).  327 
The dermal absorption of the flame retardant resorcinol bis-diphenylphosphate (RDP) was 328 
investigated in rats and monkeys. Sprague-Dawley rats and cynomolgus monkeys were 329 
dermally exposed to 100 mg of 14C-RDP spread over a shaved area representing about 20% 330 
of the animal’s surface area. Results revealed ~ 20% of the dermal dose was absorbed in rats, 331 
whereas primates absorbed only 10% of the applied dermal dose (Freudenthal, et al. 332 
2000).Very little is known about the dermal absorption of BFRs. In an early report, Ulsamer 333 
et al. studied the dermal absorption of the banned flame retardant tris (dibromopropyl) 334 
phosphate (TRIS) in rabbits. The test animals were exposed to radiolabelled 14C-TRIS via 335 
sections of fabric (10 x 12 cm) placed in contact with skin for 96 h. Results revealed that up 336 
to 17% of the applied dose was absorbed when the fabric was wetted with urine. Only 6% of 337 
the dose was absorbed when the cloth was wetted with simulated sweat, which was slightly 338 
higher than the absorption (4%) from a dry cloth (Ulsamer, et al. 1978). A more recent study 339 
used a female C57BL/6 mice model to assess the dermal bioavailability of BDE-47. Test 340 
animals were exposed to 1 mg/kg body weight of 14C-BDE 47 in acetone applied to a hairless 341 
2 cm2 skin patch. Results revealed ~62% absorption of the administered dose after 5 days 342 
while 15% remained at the site of application where skin and adipose were reported as the 343 
major depot tissues (Staskal, et al. 2005).  344 
 345 
Paradigm shift – in vivo to in vitro dermal bioavailability studies 346 
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Due to the ethical and technical issues arising from the use of lab animals in toxicology 347 
studies, the use of in vivo animal models is increasingly strongly discouraged (Jakasa and 348 
Kezic 2008). Therefore, focus has shifted to developing and validating alternative in vitro test 349 
methods, which also provide a better platform for development of predictive pharmacokinetic 350 
models. Several guidance documents for conducting in vitro skin absorption studies (OECD 351 
2004; U.S. EPA 2004; WHO 2006) are currently available rendering the application of in 352 
vitro skin models increasingly acceptable for research and  regulatory purposes. 353 
Different types of skin may be used, for example, human excised skin from surgery or from 354 
cadavers (ex vivo skin) or animal (e.g. pig) skin. Various types of diffusion cells have been 355 
employed in in vitro studies to date, and the composition of receptor fluids may vary. All 356 
these factors can influence the results of in vitro experiments (Jakasa and Kezic 2008). While 357 
several papers have reported on in vitro dermal absorption of environmental contaminants 358 
such as: polycyclic aromatic hydrocarbons, phthalates, as well as organochlorine and 359 
organophosphate pesticides (Hopf, et al. 2014; Hughes and Edwards 2010; Spalt, et al. 2009); 360 
very few in vitro studies of the dermal absorption of FRs exist. In one such study, Hughes et 361 
al. (Hughes, et al. 2001) used skin from adult hairless female mice (SKH1) mounted in flow-362 
through diffusion cells to study the absorption of 14C-BDE-209 and 14C-TDCPP at 3 363 
concentration levels. HEPES ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid ))-364 
buffered Hanks’ balanced salt solution (pH 7.4) with 10% fetal bovine serum was used as 365 
receptor fluid. Following 24 h exposure, the skin patches were washed with solvent prior to 366 
analysis of receptor fluid, skin wash and skin for chemical-derived radioactivity. BDE-209 367 
showed low penetration (0.3%) into the receptor fluid while up to 20% of the dose remained 368 
in skin after 24 h. TDCPP displayed higher penetration (39–57%) to the receptor fluid, while 369 
28–35% of administered dose remained in the skin. This was mainly attributed to its lower 370 
molecular weight and KOW than BDE-209 (Hughes, et al. 2001). The dermal absorption of 371 
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BDE-47 was studied using in vitro split-thickness skin membranes (350–410 μm, stratum 372 
corneum uppermost) of human and rat skin exposed to a single dose of ca. 10 mg/cm2 of 14C-373 
BDE-47 for 24 h. The skin patches were mounted in flow-through cells while receptor fluid 374 
(NaCl, 0.9%, w/v in water) was pumped through the receptor chambers at ca. 1.5 ml/h 375 
(Roper, et al. 2006). The dose recovered from the receptor fluid was 2% and 15% of 376 
administered BDE-47 to human and rat skin, respectively. The difference between the results 377 
of this in vitro study (Roper, et al. 2006) and the higher (62%) sorption observed in an in vivo 378 
study of dermal absorption in mice (Staskal, et al. 2005) (Table 1) may be attributed mainly 379 
to the use of 0.9% NaCl solution in water as a receptor fluid, as this may greatly reduce 380 
diffusion of the lipophilic BDE-47 to the receptor fluid (Wilkinson and Williams 2002) and 381 
does not accurately mimic actual biological conditions. Possible evidence of this is provided 382 
by the high residual levels of BDE-47 detected in the cells (57% and 33% for human and rat 383 
skin, respectively) that appeared not to diffuse to the receptor fluid (Roper, et al. 2006). 384 
While no data exists on dermal absorption of TBBP-A, a recent in vitro study reported on the 385 
percutaneous bioavailability of its precursor, bisphenol A (BPA) from human and pig skin 386 
(Zalko, et al. 2011). Viable human and pig skin patches (500 µm thickness) were maintained 387 
at the air/liquid interface using Transwell inserts while dermal/epidermal feeding was 388 
achieved via diffusion of nutrients from a modified Dulbecco’s Eagle culture medium which 389 
kept the cells alive during 72 h exposure experiments. BPA was efficiently absorbed (65% 390 
and 46% from pig and human skin, respectively) and metabolised by the cultured skin 391 
indicating the trans-dermal route contributes substantially to human exposure to BPA (Zalko, 392 
et al. 2011). However, it should be noted that TBBP-A has a much higher molecular weight 393 
and consequently, different physico-chemical properties (e.g. water solubility, partition co-394 
efficient and vapour pressure) than BPA. Furthermore, the lack of halogen atoms in BPA is 395 
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likely to enhance the rate of its percutaneous absorption compared to its tetra-brominated 396 
derivative (Garner and Matthews 1998).    397 
Given the growing evidence that suggest dermal absorption to be a potentially significant 398 
pathway of human exposure to FRs, the paucity of data on dermal bioavailability of such 399 
ubiquitous contaminants may be attributed to a combination of ethical, technical and 400 
economic issues. One alternative method with the potential to overcome such difficulties is 401 
the use of 3D human skin equivalent (HSE) models which provide a relatively cheap, 402 
commercially available, ethical, and reliable method for dermal absorption studies that is 403 
capable of producing data of relevance to human exposure. 404 
Human Skin Equivalent models (HSE)  405 
Rationale. Although the Organisation for Economic Co-operation and Development (OECD) 406 
and the European Centre for Validation of Alternative Methods (ECVAM) describe methods 407 
for assessing dermal absorption using excised in vitro human and animal skin, the lack of 408 
correlation in transdermal permeation of chemicals across species imparts a high degree of 409 
uncertainty when extrapolating results from animal models to humans. This is mainly due to 410 
variations in the stratum corneum thickness, intercellular subcutaneous lipids and/or between-411 
species differences in metabolic enzymes and their activity (Schafer-Korting, et al. 2008a). 412 
Therefore, excised in vitro human skin is preferable to animal skin (e.g. rat or pig skin) for 413 
dermal absorption testing, but is clearly less available. To overcome this shortage, HSE have 414 
been developed to provide an alternative to human skin in testing of compounds for 415 
transdermal permeability (Mertsching, et al. 2008). A protocol was developed and validated 416 
according to the OECD guidelines for percutaneous absorption by using commercially 417 
available HSE models (Table 2). The permeability of tested HSE models were compared to 418 
that of excised human epidermis, pig skin and bovine udder skin, using 9 compounds widely 419 
varying in physicochemical characteristics, including the OECD standards: testosterone, 420 
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caffeine and benzoic acid. Results revealed HSE models closely mimic the histological and 421 
physiological character of viable human skin, allowing their use for in vitro skin penetration 422 
studies, taking product-specific overpredictability into account (Hartung, et al. 2004; Schafer-423 
Korting, et al. 2008a). Consequently, several validated methods using HSE models have been 424 
approved by OECD and ECVAM for testing skin absorption, phototoxicity, corrosion and 425 
irritation by xenobiotic chemicals (Ackermann, et al. 2010; Buist, et al. 2010). 426 
Composition. HSE models can be generally classified into 2 main types: 427 
1-  Reconstructed Human Epidermis (RHE):  RHE is a human skin tissue obtained 428 
from human keratinocytes cultured on an inert polycarbonate medium. One key advantage is 429 
that it permits growth of donor epidermal cells in a serum-free culture environment. After 430 
rapidly proliferating preparative keratinocyte cultures have been obtained, the epidermal cells 431 
yielded are seeded on inert filter substrates, which are then raised to the air-liquid interface in 432 
a humidified-air incubator. A fully-defined nutrient medium feeds the basal cells through the 433 
filter substratum. After 14 days, a stratified epidermis is formed that closely resembles human 434 
epidermis in vivo (Figure 3) (Boelsma, et al. 2000). 435 
Morphologically, these cultures exhibit a well-stratified epithelium and cornified epidermis 436 
with significantly improved barrier function and metabolic activity (Boelsma, et al. 2000). 437 
Differentiation markers such as suprabasal keratins, integrin b4, integrin a6, fibronectin, 438 
involucrin, filaggrin, trichohyalin, type I, III, IV, V and VII collagen, laminin, heparan sulfate 439 
and membrane-bound transglutaminase are expressed similar to those of the human epidermis 440 
(Brinkmann, et al. 2013; Mehul, et al. 2004). 441 
Several RHE models are now commercially available. The different models share the air-442 
exposed culture conditions, but differ in the support used as a dermal equivalent on which the 443 
human keratinocytes are grown (Table 2). Numerous histological and biochemical features 444 
are shared by these models, in particular epidermal stratification and differentiation, and all 445 
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produce a well-defined stratum corneum as a result of tightly regulated expression of 446 
differentiation-related genes (Boelsma, et al. 2000; Zhang and Michniak-Kohn 2012). 447 
2- Full-Thickness skin (FT): Paracrine signaling between dermal fibroblasts (FB) and 448 
epidermal keratinocytes (KC) is believed to modulate skin responses during contact irritant or 449 
allergic reactions. Dermal FB also play an important role in photo-aging, photo-damage, 450 
wound healing and cancer progression. To enable in vitro investigation of these and other 451 
dermal phenomena in which FB-KC interactions are important,  FT skin models composed of 452 
a FB-containing dermis/KC-containing epidermis have been developed (Schafer-Korting, et 453 
al. 2008b; Semlin, et al. 2011). In order to test possible immunological reactions on skin, 454 
Langerhans cells (LCs) can be introduced into FT skin substitutes (Regnier, et al. 1997). 455 
Percutaneous absorption of chemicals is due to two different routes of passive diffusion. The 456 
first is trans-epidermal diffusion via inter- or trans- cellular pathway across the stratum 457 
corneum, whereas the second is trans-appendageal diffusion via hair follicles and associated 458 
sebaceous glands. The presence of appendages in the FT models may represent another 459 
advantage added to their superiority over RHE models for biotransformation-linked toxic 460 
endpoints (Ackermann, et al. 2010; Curren, et al. 2006). However, the scarce information 461 
available to date, indicates a complex relationship between percutaneous absorption, skin 462 
thickness and lipophilicity of test compounds (Wilkinson, et al. 2006). This is further 463 
compounded by factors like: exposure vehicle, diffusion cell design and receptor fluid 464 
(Schafer-Korting, et al. 2008b). 465 
General Protocol for in vitro percutaneous absorption studies. Each HSE model is supplied 466 
with its respective receptor/culture fluid and its percutaneous absorption protocol. Generally, 467 
the protocol involves mounting the fully-developed skin patches at the air-liquid interface of 468 
a permeation device (e.g. Franz-cell type diffusion cells, Mattek® permeation device, see SI 469 
section for further details) while in contact with the receptor fluid. The test compound is then 470 
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applied to the surface of the stratum corneum and incubated for the required exposure time 471 
(usually 24 h). The receptor fluid is sampled and replaced at fixed time intervals. At the end 472 
of the exposure period, the skin surface is washed/wiped clean of any residual contaminant 473 
remaining, prior to collection of the receptor fluid and cell culture for chemical analysis 474 
(Figure 4).  475 
Future perspectives and challenges facing dermal absorption studies of FRs  476 
Although current commercially available HSE models may provide a useful alternative to 477 
study the human dermal absorption of FRs, there remains several challenges and research 478 
gaps that need to be addressed in the near future. These include: 479 
• The lack of experimental data –either in vivo or in vitro– relevant to the dermal 480 
bioavailability of a wide range of FRs in human. Such paucity of information 481 
regarding the dermal pathway hinders the current efforts for accurate risk assessment 482 
of various FRs. Furthermore, it complicates the pharmacokinetic modelling studies 483 
aiming to understand the relationship between external exposure and human body 484 
burdens of FRs.    485 
• The diverse nature and wide range of physico-chemical parameters of organic FR 486 
chemicals (Table SI-1). Contaminant properties like: Log KOW, molecular weight, size 487 
and water solubility were reported to affect the dermal absorption of PCBs (Garner 488 
and Matthews 1998). Furthermore, the difference in protein binding affinities of 489 
various FRs may also influence their permeation through the skin barrier. This will be 490 
of particular interest if OATPs were involved in mediating the active transport process 491 
of FRs across the human epidermis. Therefore, the chemical diversity and co-492 
existence of various BFRs and PFRs in different environmental samples are likely to 493 
present a challenge to environmental scientists trying to mimic in vivo scenarios.  494 
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• FR chemicals with similar/comparable molecular weight, size and Kow can exist in 495 
different isomeric forms (e.g. HBCD isomers), which might adopt various structural 496 
characteristics (e.g. planarity) and exhibit different physico-chemical properties (e.g. 497 
water solubility). This is also likely to constitute an important factor influencing the 498 
dermal bioavailabilty of such iso-baric compounds.   499 
• Despite the huge advances in production and validation of HSE models in the past 500 
few years, further improvements are still required to closely mimic the in vivo 501 
situation. The presence of hair follicles, sweat and sebaceous glands provides further 502 
potential pathways for percutaneous penetration. The dermis in vivo is continously 503 
perfused by the subcutaneous vasculature, which can rapidly remove permeants 504 
reaching the epidermal-dermis interface, allowing for further diffusion of the 505 
permeant through the skin layers. This system can be mimicked in vitro via the use of 506 
dynamic in-line flow through diffusion cells (Table SI-2). However, further validation 507 
and standardisation of test protocols using this model is still required to gain the 508 
approval of the regulatory bodies and research organisations.   509 
• Transdermal metabolism has been reported as a major mediator for percutaneous 510 
absorption of PCBs (Garner, et al. 2006). Currently, very little is known about the 511 
dermal biotransformation of BFRs and PFRs (Hughes, et al. 2001). Enhanced 512 
understanding of percutaneous metabolic pathways and identification of the 513 
metabolites thus formed in humans thus appears important, if the reliability of risk 514 
assessment of these contaminants is to be improved.  515 
• The excretion of xenobiotic chemicals and their metabolites in sweat and hair follicles 516 
has been well documentd in literature (De Giovanni and Fucci 2013; Parle and Jadhav 517 
2007). Therefore, biotransformation may not be the only dermal contaminant-removal 518 
mechanism in human. Further research is required to understand the role of eccrine 519 
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sweat and hair follicles as excretion routes for FRs. Consequently, the in vitro human 520 
skin models may consider the dermal bioavailability of FRs as an equilibrium process.    521 
• While HSE models have been widely exploited in the pharmaceutical and cosmetic 522 
fields; to the authors’ knowledge, they are yet to be applied for studying dermal 523 
absorption of FRs or any other organic contaminants. This is likely to create several 524 
challenges for analytical method development, exposure protocols and modelling of 525 
the results. Furthermore, in vitro dermal studies carried out for the purpose of risk 526 
assessment should also include scenarios that mimic real life exposure to the test 527 
compounds. This includes exposure to environmentally-relevant concentrations via 528 
appropriate exposure media. Previous studies have shown that dermal absorption of 529 
PCBs from contaminated soils was different from direct application of PCBs in 530 
solution to the skin (Mayes, et al. 2002). In addition, dermal bioavailability has also 531 
been shown as influenced by the age of the contaminant in soil and its organic content 532 
(Spalt, et al. 2009). Similar factors are likely to affect percutaneous absorption of 533 
BFRs and PFRs. Therefore, several exposure scenarios addressing dermal uptake 534 
from a range of environmental media (e.g. indoor dust, soil, sweat and consumer 535 
products) will be needed for full characterisation of the exposure arising from human 536 
dermal exposure to FRs.                       537 
 538 
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 545 
Supplementary data 546 
Specific details on physico-chemical parameters, uses, toxicokinetic profiles and main 547 
exposure pathways of key brominated and phosphorous flame retardants in addition to 548 
different in vitro dermal absorption protocols are available as supplementary data.  549 
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Tables 864 
Table 1: Summary of in vivo and in vitro methods applied for studying dermal absorption of FR chemicals. 865 
Compound Skin  type 
Study 
type Dosing 
Exposure 
time 
Absorption (% of 
administered dose) Ref. 
PCBs # 52, 101, 
108, 118, 138, 153, 
170, 180 
Human In vivo 
PCBs (5 mg) were dissolved in 
DCM and applied to the carrier 
(4cm2 cotton cloth or 28cm2 
aluminium foil) prior to fixing to 
the skin 
0.66-1 day Up to 6% for PCB-153 
(Schmid, 
et al. 
1992) 
PCBs (14C-Aroclor 
1260 mixture) 
Rhesus 
monkeys  In vivo 
500 mg of 70 µg/g PCB-spiked 
soil applied to 12 cm2 of skin 12-24 h 
3.43 ± 0.35%  for 12 h 
and 4.26 ± 0.52% for 24 h 
(Mayes, 
et al. 
2002) 
PCBs # 4, 15, 47, 
155 
Male F-344 
rats In vivo 
0.4 mg/kg bw applied to 1 cm2 of 
skin 
1, 4, 8, 12, 
24, 48, 72, 
96, and 336 
h 
From ca. 100% for PCB-4 
to ca. 30% for PCB-155. 
(Garner 
and 
Matthews 
1998) 
BDE-47 Female C57BL/6 mice In vivo 
1 mg/kg bw applied to 2 cm2 of 
skin 5 days 62% 
(Staskal, 
et al. 
2005) 
40 
 
BDE-209 and 
TDCPP 
female mice 
(SKH1) In vitro 
6, 30 and 60 nmol in THF for 
BDE-209; 20, 100 and 200 pmol 
in acetone for TDCPP 
24 hrs 
2–20% in skin, 0.07-
0.34% in receptor fluid for 
BDE-209. 39–57% in skin 
and 28–35% in receptor 
fluid for TDCPP 
(Hughes, 
et al. 
2001) 
BDE-47 
Human and rat 
skin (350–410 
μm) 
In vitro 10 mg/cm2 applied in acetone. 24 hrs 
2-15% in 0.9% NaCl 
receptor fluid; 57% and 
33% remained in cells for 
human and rat skin, 
respectively. 
(Roper, 
et al. 
2006) 
BISPHENOL-A 
(Precursor to 
TBBP-A) 
Pig Ear Skin 
and Human 
skin 
In vitro 
50, 100, 200, 400 and 800 nmol 
were applied 
in 60 µL ethanol/phosphate buffer 
(pH 7.4) 
24, 48 and 
72 h 
Human skin (45.6 ± 
6.2%),  pig skin (65.3 ± 
8.2%)  
BPA–glucuronide formed 
in human skin , 
corresponding to 7 ± 2, 16 
± 3 and 30.± 3 nmol at 24, 
48 and 72 h, respectively. 
(Zalko, et 
al. 2011) 
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Table 2: Characteristics of commercially available HSE models. 872 
Brand Name Scaffold material Source Dermis Manufacturer 
Episkin™ 
Collagen 
(0.38 cm2) 
Keratinocytes(Mammary/Abdo
minal samples obtained from 
healthy consenting Donors 
during plastic surgery) 
NO L’Oreal, Nice,France 
Skinethic™ 
Polycarbonate 
membrane 
( 0.5 cm2 ) 
Keratinocytes (neonatal 
foreskin tissue or adult breast 
tissue) 
No L’Oreal, Nice,France 
EpidermTM 
Collagen coated 
Polycarbonate 
(9mm diameter) 
Human keratinocytes (neonatal 
foreskin adult breast skin) 
No 
MatTek Corporation, 
MA, USA 
EpidermFT™ Collagen 
Human keratinocytes (neonatal 
foreskin adult breast skin) 
human fibroblasts (neonatal 
skin, adult skin) 
Yes 
MatTek Corporation, 
MA, USA 
EST-1000 
Polycarbonate 
membrane 
Keratinocytes (neonatal 
foreskin) 
No 
CellSystems, 
Troisdorf 
Germany 
AST-2000 Collagen Human Keratinocytes Yes 
CellSystems, 
Troisdorf 
Germany 
Phenion® FT 
Model 
Bovine, cross 
linked,lyophilized 
collagen 
(1.3 cm dia) 
Primary human keratinocytes 
(neonatal foreskin), human 
fibroblasts (neonatal foreskin) 
Yes 
Henkel, Duesseldorf, 
Germany 
StrataTest® 
Collagen I 
(0.6 cm2 ) 
immortalized, human NIKS® 
keratinocytes 
dermal fibroblasts 
Yes 
Stratatech 
Corporation Madison 
WI, USA 
Epistem ® LSE Collagen 
Primary human keratinocytes 
and dermal fibroblasts. 
Yes 
Epistem limited, 
Manchester, UK. 
StratiCell® 
EPI/001 
Polycarbonate 
membrane 
Primary human keratinocytes No 
Straticell 
Corporation, 
Gembloux, Belgium. 
StratiCell® 
Mel/001 
Polycarbonate 
membrane 
Primary human keratinocytes 
and melanocytes. 
No 
Straticell 
Corporation, 
Gembloux, Belgium. 
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Figures 874 
Figure 1: Major pathways of human exposure to FRs. 875 
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Figure 2: Anatomy of the human skin. 891 
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Figure 3: General stages of development of HSE model.  899 
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Figure 4: General protocol for percutaneous absorption studies using in vitro HSE 910 
models. 911 
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